본문 바로가기 주메뉴 바로가기
  • HOME
  • Public Relations
  • GC Cell News

GC Cell News

GC Cell is pushing ahead with the development of off-the-shelf CAR-CIK cell therapeutics
2021-03-22
GC Cell is pushing ahead with the development of off-the-shelf CAR-CIK cell therapeutics
GC Cell has presented a vision for future growth that could grow into the company that specializes in immunotherapeutics by developing CAR-CIK cell therapy overcoming limitations of existing CAR-T cell therapeutics and expanding cell-and-gene-therapy CDMO universal cell therapy using the CAR-T cell which is about to undergo a US clinical trial, we plan to diversify our business by increasing CDMO and immune stimulants/anticancer product areas from the current business structure which focuses on the production and sales of Immuncell-LC injection.
In particular, GC Cell is scheduled to develop a frozen formulation of universal CAR-CIK cell therapeutics by combining the CAR-T cell therapy platform technology secured by the recent two patent registrations and the production know-how accumulated for more than 10 years of CIK therapeutics Immuncell-LC injection.
Along with this, we plan to expand the CDMO business for cell-and-gene therapy, which is rapidly growing in the global market, based on Cell Center, the largest cell therapy production facility in Korea.
Cell Center is equipped with cGMP-level advanced facilities and production equipment optimized for the production of cell therapeutics. It is a production facility that meets global standards by introducing advanced management and production systems. Through this, we already have a wealth of experience in producing investigational products in the US as well as in Korea.
On the other hand, CAR-T cell therapeutics targeting solid tumors currently being developed are undergoing additional research to enter a Phase 1/2a clinical trial in the US. However, due to delay in cGMP's clinical trial sample production schedule due to the COVID-19 pandemic in the U.S., IND applications are expected to be available within the second quarter of 2022.
With the development of CAR-CIK cell therapeutics, cancer patients can be treated with cell-and-gene therapy products at any time without restrictions for blood collection, manufacturing period, or side effects.
In addition, attributed to the success of Immuncell-LC injection, which has achieved the No. 1 anticancer drug sales in Korea, we will focus on our company-wide capabilities to develop off-the-shelf CAR-CIK cell therapeutics.
Next
GC Cell Completes pct for entry into the global market
Previous
GC Cell Becomes a CDMO Specializing in Cell Therapeutics